Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
Status:
Completed
Trial end date:
2017-12-07
Target enrollment:
Participant gender:
Summary
This trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to
decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators:
Charite University, Berlin, Germany Cliniques universitaires Saint-Luc- Université Catholique de Louvain ZonMw: The Netherlands Organisation for Health Research and Development